1A. Personal Details Full Name Khaled Fathi Hassan Greish Present
Total Page:16
File Type:pdf, Size:1020Kb
1a. Personal details Full name Title First name Second name(s) Family name Dr. Khaled Fathi Hassan Greish Present position Associate Professor /Adjunct Associate Professor Organisation/Employer Arabian Gulf University/University of Utah-USA Contact Address Department of Molecular medicine/ Department of Pharmaceutical Chemistry Aljawhara Centre for molecular medicine Work telephone 1723793 Mobile 34358697 Email [email protected] Personal website (if http://www.otago.ac.nz/phal/people/profile/index.html?id=1071 applicable) 1b. Academic qualifications Year Qualification Discipline University/institute 2006 Ph.D Targeted anticancer Graduate School of Medical Sciences, therapy Kumamoto University, Japan 1997 Master Clinical oncology Suez Canal University, Ismailia, Egypt 1992 MB.B.Ch Medicine and surgery Faculty of Medicine, Suez Canal with honor University, Ismailia, Egypt 1c. Professional positions held Organisation Year Job title 2015- Associate professor level 7 Department of Molecular medicine, Arabian gulf university 2014- Adjunct Associate Professor Department of pharmaceutical sciences, University of Utah, and Nano institute of Utah 2014- Senior Lecture Department of Pharmacology and Toxicology, University of Otago, New Zealand July 2011- Lecturer Department of Pharmacology and Toxicology, University of Otago, New Zealand 2010-2011 Visiting Professor Utah-Inha DDS Center, South Korea 2009- Research assistant professor Department of pharmaceutical sciences, University of Utah, and Nano institute of Utah 2008-2009 Research associate Department of pharmaceutical sciences, University of Utah 2006-2008 JSPS post-doctoral Fellow Faculty of Pharmaceutical Sciences, Sojo University , Japan 1995-2001 Assistant lecturer Faculty of Medicine, Suez Canal University, Ismailia, Egypt 2011- lecturer Faculty of Medicine, Suez Canal University, Ismailia, Egypt 1d. Present research/professional speciality Nanomedicine, Anticancer drug delivery, and tumor vascular biology 1e. Total years research experience 23 (post- master) years 1f. Professional distinctions and memberships (including honours, prizes, scholarships, boards or governance roles, etc) 2019, Invited speaker: 2nd Pearl International Pediatric Conference, Bahrain 2019 Invited Speaker : The millennium biotechnology pan-Arab conference & bio- business forum" MBPAC, Bahrain 2019, Plenary speaker, 10th RAKMHSU Students Scientific Conference, UAE 2019 Invited Speaker, University De Catania, Italy 2017, Invited speaker, 3th International Conference and Exhibition on Nanomedicine and Pharmaceutical Nanotechnology, Rome, Italy: https://nanotechnology.pharmaceuticalconferences.com/speaker/2017/khaled-greish- arabian-gulf-university-bahrain 2017, Best presentation, University De Catania, Italy 2015,Invited Speaker, Kuwait University 2015, Session chair, Controlled Release Society: 40th annual meeting, UK. 2014, Chair of Seattleite meeting committee, Controlled release Society 2014, Early career award for distinction in research http://www.otago.ac.nz/news/news/otago073898.html 2014, 3rd International Conference on Drug Discovery and Development, Dubai, UAE: Best paper award 2014, invited speaker, French Society for Nanomedicine (SFNano), Porto, Portugal 2014, invited speaker, 3rd International Conference on Drug Discovery and Development, Dubai, UAE. 2013, invited speaker, Joint Australasian Pharmaceutical Science Association Conference, and New Zeeland Controlled Release Society meeting. Dunedin , New Zealand 2013, invited speaker, Nano- institute of Utah Seminar, Salt lake city, Utah. 2013, invited Speaker, National Centre for Natural Products Research, the University of Mississippi, Oxford USA. 2013, invited Speaker, 15th FDB Annual Conference, Dunedin, New Zealand. 2012, Invited speaker, Controlled Release Society: 37 annual meeting. Quebec, Canada. 2012, Session chair, Controlled Release Society: 37 annual meeting, Quebec, Canada. 2012, Invited speaker for the 12th European Symposium on Controlled Drug Delivery. Egmondaan Zee, The Netherlands 2010, Controlled Release Society: CRS membership of the inaugural College of Fellows. 2008, Invited Speaker, CRS webcast seminar 2008, CRS -Nagai post-doctoral achievement award. 2007, Invited Speaker, the 23rd Japan Drug Delivery System research society meeting, Kumamoto, Japan. 2007, Award of Young Scientists Refereeing Program (Biomaterials). 2006, Japanese Society for Promotion of Science (JSPS) post-doctoral Scholarship. 2001, Ministry of Education, Culture, Sports, Science and Technology, Government of Japan (MONBUSHO); Scholarship for studying Ph.D., Japan. I am reviewer for; Biomaterials, ActaBiomaterialia, Journal of controlled release, Nanomedicine, Molecular pharmaceutics, The Journal of Gene Medicine, Journal of drug targeting, Drug Discovery today, Nanotechnology, Science and Applications, Nanomedicine, Medical Science Monitor. Professional Affiliations/ Memberships (List) Satellite meeting committee, Controlled Release Society Centre for Translational Cancer Research, Otago University New Zealand local chapter of Controlled Release Society, committee member Formulation and Delivery of Bioactives (FDB), steering committee member Center for Bioengineering and Nanomedicine , Otago University MARS Spectral Molecular Imaging group Nano - institute of Utah Controlled Release Society Japanese Cancer Society Japanese Drug Delivery System Society Egyptian Medical Syndicate, 1991-present (a) Research Expertise Developing and evaluating anticancer drug delivery systems to improve the efficacy and safety of approved and novel anticancer chemotherapeutics. Selective targeting of chemotherapeutic drugs by conjugation of folic acid and glucose to nanodeliverymiceller system. Development of oral Nan-delivery systems for oral delivery of targeted anticancer agents. Use of low voltage alternate current to locally enhance drug delivery. Evaluations of the unique tumor cell properties that favorers enhanced uptake of the novel drug delivery formulations. Extending the use of delivery systems to other disease conditions such as chronic neuropathic pain. Evaluation of the use of gold and silver nanoparticles for concomitant diagnostic and treatment application (theranostic applications). 1g. Total number of peer Journal Books, book Conference Patents reviewed publications and articles chapters, books proceedings patents edited 85 10 >150 3 These publications have received 6317 citations with an h index of 33 according to google scholars. https://scholar.google.co.nz/citations?user=gKwc5WYAAAAJ&hl=en ORCI ID: https://orcid.org/0000-0002-0787-7070 Researcher ID: P-4938-2017 PART 2 2a. Research publications and dissemination Peer-reviewed journal articles 1. H. Alimoradi, Khaled Greish, Allan Gamble, Gregory Giles: Controlled Delivery of Nitric Oxide for Cancer Therapy, Pharmaceutical Nanotechnology, 7(4) 2019 . DOI: 10.2174/ 2211738507666190429111306. 2. V. Pittalà, L. Vanella, C.B. Maria Platania, L. Salerno, M. Raffaele, E. Amata, A. Marrazzo, G. Floresta, G. Romeo, K. Greish, Synthesis, in vitro and in silico studies of HO-1 inducers and lung antifibrotic agents, Future medicinal chemistry 11(13) (2019) 1523-1536. 3. R. Mohammadpour, M.A. Dobrovolskaia, D.L. Cheney, K.F. Greish, H. Ghandehari, Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications, Advanced drug delivery reviews (2019). 4. M.A. Morsy, S. Gupta, A.B. Nair, K.N. Venugopala, K. Greish, M. El-Daly, Protective Effect of Spirulina platensis Extract against Dextran-Sulfate-Sodium-Induced Ulcerative Colitis in Rats, Nutrients 11(10) (2019) 2309. 5. H. Alimoradi, A. Barzegar-Fallah, I. Sammut, K. Greish, G. Giles, Encapsulation of tDodSNO generates a nitric oxide releasing nanoparticle, Free Radical Biology and Medicine 128 (2018) S117. 6. H. Alimoradi, A. Barzegar-Fallah, I.A. Sammut, K. Greish, G.I. Giles, Data characterizing the biophysical and nitric oxide release properties of the tDodSNO–Styrene maleic anhydride nanoparticle SMA-tDodSNO, Data in brief 21 (2018) 1771-1775. 7. H. Alimoradi, A. Barzegar-Fallah, I.A. Sammut, K. Greish, G.I. Giles, Encapsulation of tDodSNO generates a photoactivated nitric oxide releasing nanoparticle for localized control of vasodilation and vascular hyperpermeability, Free Radical Biology and Medicine 130 (2019) 297-305. 8. Alimoradi, K. Greish, A. Barzegar-Fallah, L. Alshaibani, V. Pittalà, Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity, International journal of nanomedicine 13 (2018) 7771. 9. F. Bahman, S. Elkaissi, K. Greish, S. Taurin, Polymeric Micelles in Management of Lung Cancer, Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer, Academic Press2019, pp. 193-216. 10. F. Bahman, K. Greish, S. Taurin, Nanotechnology in insulin delivery for management of diabetes, Pharmaceutical nanotechnology (2019). 11. K. Greish, Recent and future advances in anticancer drug delivery: an interview with Khaled Greish, Therapeutic delivery 9(6) (2018) 409-412. 12. K. Greish, A. Alqahtani, A. Alotaibi, A. Abdulla, A. Bukelly, F. Alsobyani, G. Alharbi, I. Alkiyumi, M. Aldawish, T. Alshahrani, The Effect of Silver Nanoparticles on Learning, Memory and Social Interaction in BALB/C Mice, International journal of environmental research and public health 16(1) (2019) 148. 13. K. Greish, M. Fateel, S. Abdelghany, N. Rachel, H. Alimoradi, M. Bakhiet, A. Alsaie, Sildenafil citrate improves the delivery and anticancer activity of doxorubicin